2. Institute for Transfusion Medicine, University Hospital Essen, Virchowstr. 179, 45147 Essen, Germany.
In solid tumors HLA-G is a clear immune-escape molecule inhibiting innate and adaptive effectors. This is not systematically demonstrated for B-cell malignancies, leading to a confused overall role for HLA-G in cancer likely due to the fact that malignant B-cells are as much of immune origin as the anti-tumoral effectors themselves.
Keywords: HLA-G, CLL, immune-escape, ILT2, cancer, B-cell malignancy, multiple myeloma